GPR55

Chr 2

G protein-coupled receptor 55

Also known as: LPIR1

GPR55 encodes a G-protein coupled receptor that binds lysophospholipid ligands and activates multiple intracellular signaling pathways, including calcium release and RHOA-mediated cytoskeletal changes. The gene shows very low constraint against loss-of-function variants (pLI ~0, LOEUF 1.7), and no established Mendelian diseases have been definitively linked to GPR55 mutations in the pediatric population. While the receptor may influence lipid metabolism and cellular morphology, its role in human genetic disease remains unclear.

Summary from RefSeq, UniProt
Research Assistant →
0
Active trials
55
Pubs (1 yr)
29
P/LP submissions
0%
P/LP missense
1.71
LOEUF
Multiple*
Mechanism· predicted
Clinical SummaryGPR55
Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
29 unique Pathogenic / Likely Pathogenic· 50 VUS of 85 total submissions

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint
1.71LOEUF
pLI 0.000
Z-score 0.10
OE 0.96 (0.541.71)
Tolerant

Highly tolerant — LoF variants common in population

Missense Constraint
0.71Z-score
OE missense 0.85 (0.750.97)
159 obs / 186.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios
LoF OE0.96 (0.541.71)
00.351.4
Missense OE0.85 (0.750.97)
00.61.4
Synonymous OE1.09
01.21.6
LoF obs/exp: 7 / 7.3Missense obs/exp: 159 / 186.4Syn Z: -0.62
DN
0.6839th %ile
GOF
0.79top 10%
LOF
0.2777th %ile

This gene has evidence for multiple mechanisms of pathogenicity (gain-of-function and dominant-negative). Both the Badonyi & Marsh prediction and the broader genomic evidence point to gain-of-function as the predominant mechanism. Different variants in this gene may act through different mechanisms — interpret in context of the specific variant.

GOFprediction above median
DNprediction above median

Note: In-silico variant effect predictors (SIFT, PolyPhen, REVEL, CADD) may underestimate pathogenicity of missense variants in genes with GOF or DN mechanisms. Consider functional evidence and clinical context.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

85 submitted variants in ClinVar

Classification Summary

Pathogenic29
VUS50
Likely Benign3
Benign1
29
Pathogenic
50
VUS
3
Likely Benign
1
Benign

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
0
0
29
0
29
Likely Pathogenic
0
0
0
0
0
VUS
0
48
2
0
50
Likely Benign
0
3
0
0
3
Benign
0
1
0
0
1
Total05231083

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

Protein Context — Lollipop Plot

GPR55 · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

3D Protein StructureAlphaFold

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

No active trials found for this gene.

Search ClinicalTrials.gov →
Clinical Literature
Open Research Assistant →
Key Publications
Landmark & review papers · by relevance
PubMed
The Basal Pharmacology of Palmitoylethanolamide.
Rankin L et al.·Int J Mol Sci
2020Review
Cannabinoids in the landscape of cancer.
Mangal N et al.·J Cancer Res Clin Oncol
2021Review
Top 5 results · since 2015Search PubMed ↗